Three days goes by, nothing happens
In parallel with rapid shifts in the small intestinal microbiota, impairments in the regulation of glucose homeostasis via small intestinal lipid sensing occur following just 3 days of HFD feeding 130
Watch now To view or add a comment, sign in GLP1, Wegovy, has recently been FDA-approved for MASH patients with moderate-to-advanced fibrosis hot on the heels of last years approval of first-mover, Rezdifrra
Other GLP-1 receptor agonists such as liraglutide 3mg (Saxenda) or tirzepatide (Mounjaro, per NICE TA1026) may be considered according to local commissioning arrangements and NICE guidance
9 As a result, employers may find it difficult to decide whether they should cover these drugs or exclude them
Key Takeaway: Bioavailability is not just a marketing term